Welcome to our dedicated page for OREXO AB SP/ADR news (Ticker: ORXOY), a resource for investors and traders seeking the latest updates and insights on OREXO AB SP/ADR stock.
Orexo AB (publ) is a Swedish pharmaceutical company that has been operating for over 25 years with a focus on developing improved pharmaceuticals based on proprietary formulation technologies. The company offers innovative treatment solutions for patients with opioid use disorder and related diseases in the US market and collaborates with partners globally for products targeting various therapeutic areas. With total net sales amounting to SEK 639 million in 2023, Orexo is committed to providing high-quality pharmaceutical solutions to meet significant medical needs. The company's recent accomplishments include the extension of patent protection for its nasal epinephrine powder product, OX640, and the successful issuance of senior secured social bonds.
Rhea-AI Summary
Orexo AB plans to issue new senior secured callable floating rate social bonds worth SEK 500,000,000. The company aims to refinance existing bonds and finance acquisitions or investments. Orexo also announced a Tender Offer for existing bondholders at 100.750% of the nominal amount plus interest. The Tender Offer expires on March 14, 2024, subject to the successful issue of the New Social Bonds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Orexo and Sobi announced the advancement of their collaboration following a successful exploratory feasibility study with Orexo's AmorphOX drug delivery platform. The study confirmed the biomolecule's activity retention after formulation with AmorphOX. Orexo has patent applications for AmorphOX formulations related to biomolecules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
In the press release from February 8, 2024, Orexo AB reported a positive EBITDA in H2, setting the target for FY 2024. The total net revenues were SEK 166.0 m, with the US Pharma segment (Zubsolv® US) net revenues of SEK 151.3 m. The MODIA® study didn't meet the primary end-points, but showed high rates of treatment response. Robin Evers was elected as a board member, and the FDA accepted the New Drug Application filing for review of OX124, a high-dose rescue medication for opioid overdose with naloxone. The financial outlook for 2024 includes a 2-5% growth in the buprenorphine/naloxone market and positive EBITDA for the FY 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary
Orexo AB (publ.) announces the presentation of its nasal epinephrine powder product OX640 at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The product is based on the proprietary AmorphOX drug delivery platform and has the potential to provide allergic patients with a needle-free, convenient, and rapidly acting allergy rescue product. Dr. Anne K Ellis, an esteemed expert in the field of allergy, will present the abstract at the high-profile late breaking oral abstract session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Orexo AB (ORX) announces the NDA acceptance for OX124, a nasal rescue medication for opioid overdose, by the US FDA. OX124, based on Orexo´s amorphOX® platform, contains high-dose naloxone and targets synthetic opioid overdoses. The PDUFA date is set to July 15, 2024, with a potential US launch later that year. The medication's unique formulation and rapid absorption make it a promising solution to combat fatal opioid overdoses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Orexo, a pharmaceutical company based in Sweden, reported Q3 2023 financial results with total net revenues of SEK 156.1 million. The US Pharma segment generated net revenues of SEK 140.4 million. The company filed OX124, a high-dose rescue medication for opioid overdose, with the FDA. The MODIA® study showed high rates of treatment response. Orexo aims to reach EBITDA in balance for H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Robin Evers joins Orexo AB's Board of Directors, replacing Henrik Kjaer Hansen. Evers brings 25 years of experience in the pharmaceutical industry and expertise in biologics and vaccines. Orexo focuses on pharmaceutical development with its scalable formulation platform amorphOX®. James Noble, Chairman of the Board, welcomes Evers and thanks Hansen for his contributions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Orexo appoints Nomination Committee for the upcoming Annual General Meeting in 2024. The committee will prepare proposals for various positions and fees, and shareholders can submit their proposals by February 24, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Orexo AB announces election of new board member and dismissal of current member at extraordinary general meeting. Remuneration to the board of directors to continue as previously resolved. Complete proposals available on Orexo's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Orexo reports top line results of study evaluating the efficacy of MODIA for the treatment of opioid use disorder
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of OREXO AB SP/ADR (ORXOY)?
The current stock price of OREXO AB SP/ADR (ORXOY) is $1.85 as of January 22, 2025.
What is the market cap of OREXO AB SP/ADR (ORXOY)?
The market cap of OREXO AB SP/ADR (ORXOY) is approximately 63.8M.
What is Orexo AB (publ) known for?
Orexo AB (publ) is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs.
In which market does Orexo provide treatment solutions for patients?
Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases in the US market.
What are Orexo's recent accomplishments?
Orexo extended patent protection for its nasal epinephrine powder product, OX640, and successfully issued senior secured social bonds.
How does Orexo collaborate for products targeting therapeutic areas?
Orexo collaborates with partners globally for the development and commercialization of products targeting various therapeutic areas.
What was Orexo's total net sales in 2023?
Orexo's total net sales in 2023 amounted to SEK 639 million.
OREXO AB SP/ADR
OTC:ORXOY
ORXOY Rankings
ORXOY Stock Data
63.83M
34.29M
Drug Manufacturers - Specialty & Generic
Healthcare
United States of America
Uppsala